From Name:
From Email:
To Name:
To Email:

Optional Message:

Regeneron and Teva's fasinumab hit with FDA clinical hold

from FierceBiotech

Drug development partners Teva and Regeneron have seen a midstage study of their experimental pain med fasinumab put on a clinical hold by the U.S. regulator due to safety concerns. The pair's anti-NGF fasinumab was being studied in a Phase IIb trial in chronic low back pain, among others tests including osteoarthrosis pain. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063